Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 23

  • Cover caption: On this cover, YDJC, an IBD susceptibility gene of IBD, is portrayed as a sentinel molecule that suppresses SREBP2-driven cholesterol biosynthesis in CD4+ T cells. By limiting cholesterol production, YDJC prevents excessive Th1 cell activation and proinflammatory cytokine release, thereby maintaining immune homeostasis in the intestinal mucosa, and pointing to a novel therapeutic target for IBD.

    Refer to: YDJC restrains Th1 cell differentiation by blocking SREBP2-mediated cholesterol biosynthesis to alleviate mucosal inflammation in inflammatory bowel disease. pp:15–30.

Search

Advanced search

Quick links